ARTICLE | Clinical News

Genmab Humax-CD4 Phase II psoriasis data

November 12, 2001 8:00 AM UTC

Genmab (CSE:GEN, NMarkt:GE9D) said that initial data from 79 of 85 psoriasis patients in a Phase II study of its Humax-CD4 antibody showed a significant dose response in doses up to 160 mg. In the 160...